Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

One-year Data Demonstrate Continued Safety, Consistently Positive Clinical

Results with XIENCE V

WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT III U.S. pivotal clinical trial demonstrated continued positive, statistically significant clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System at one year, including continued clinical superiority in major adverse cardiac events (MACE) and continued non- inferior rates of target vessel failure (TVF) with XIENCE V compared to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System. The results were presented at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington D.C.

These results follow the data presented earlier this year at the annual American College of Cardiology conference, wherein XIENCE V demonstrated superiority to TAXUS in the SPIRIT III trial on the study's primary endpoint of in-segment late loss at eight months with a statistically significant 50 percent reduction in late loss compared to TAXUS. (In-segment late loss is a measure of vessel renarrowing).

The SPIRIT III clinical trial of 1,002 patients demonstrated the following key results for XIENCE V at one year:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated clinical superiority to TAXUS with a statistically

significant 43 percent reduction in MACE compared to TAXUS at one year.

These MACE results are consistent with the clinically superior 44

percent reduction in MACE observed for XIENCE V at nine months. MACE is

an important clinical measure of safety and efficacy outcomes for

patients, defined as cardiac death, heart attack (myocardial infarction

or MI), or ischemia-driven target lesion revascularization (TLR driven

by lack of blood supply).

--
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Nov. 21, 2014  Particle Sciences, Inc (PSI), ... developed and manufactured a new innovative vaginal ring ... and Development arm of Exeltis Pharmaceuticals.  According to ... Management at Particle Sciences, "This vaginal ring was ... material sciences and modeling expertise.  We are thrilled ...
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014  Alta ... in Southern California , today announced ... technology. Alta will be providing the innovative BeClose system ... Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... providing the kind of affordable 24/7 care our clients ...
(Date:11/21/2014)... -- Heated dialogue in recent months about the rising cost ... Gilead,s new hepatitis C drug Harvoni® – has consumers, ... it means to put a price on patient treatment ... drug pricing is one of the most debated aspects ... business and ethical standpoint – it is also the ...
Breaking Medicine Technology:Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5
... Calif. and AMSTERDAM, Dec. 6, 2011 Agendia, ... introduction of formalin fixed, paraffin embedded tissue technology ... assays. Delivering Agendia,s tests in a paraffin embedded ... with the superior science, development and validation found ...
... Pa., Dec. 6, 2011 ViroPharma Incorporated (Nasdaq: ... HALO ) today announced positive top ... 2 clinical trial designed to evaluate the safety, ... (C1 esterase inhibitor [human)] in combination with Halozyme,s ...
Cached Medicine Technology:Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue 2ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 2ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 3ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 4ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 5ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 6ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 7ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20) 8
(Date:11/24/2014)... (PRWEB) November 24, 2014 The typical ... of the wrong ingredients. Consistently consuming a diet high ... develop stores of excess fat that typically accumulate around ... and rearing its ugly head in the form of ... When dieters make the decision to rid themselves of ...
(Date:11/24/2014)... PA (PRWEB) November 24, 2014 "My ... he was trying to cross the street in his ... driver never saw him. I came up with this ... visible at night." , He developed the Safety Lites ... or in low-lighting conditions. The device ensures that motorists ...
(Date:11/23/2014)... (PRWEB) November 24, 2014 Tbdress.com ... be available online on Nov. 28, 2014. The special offer ... , Tbdress.com is one of the world’s largest women’s ... styles and colors. People can enjoy great discounts on that ... can enjoy free delivery (for orders above $89). , People ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released a ... are available at low rates up to 30% off. ... new emergency doors. The emergency door adopts fireproof material ... several colors. All of the products are top-quality guaranteed. ... not as easy as many people think. As ...
(Date:11/23/2014)... 2014 AngelWeddingDress.com has recently ... selection of beach wedding dresses. “If you are looking ... AngelWeddingDress.com as soon as possible. Here you can enjoy ... manager says. , Holding a big marriage ceremony is ... a beautiful beach wedding dress is uppermost priority. Ophelia, ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... Multiple sclerosis patients who directly confronted the stress of the ... to cope with the situation by focusing on feelings. This ... researchers of the University of Haifa, the Technion-Israel Institute of ... for multiple sclerosis to date, it is important to uncover ...
... it comes to relationships and the content of play, ... The thesis examines what children negotiate over, how ... show that young children are skilled negotiators. Torgeir ... play, which negotiation strategies are appropriate and which aren,t. ...
... because thyroid hormones play critical role in fetal development, ... Exposure to flame-retardant chemicals may reduce a pregnant woman,s ... role in fetal brain development, a new study shows. ... in a large number of consumer products, including cars, ...
... Using likes of Shrek and Dora to market treats ... (HealthDay News) -- Popular cartoon characters are influencing the ... a positive way, a new study suggests. , Researchers ... with characters such as Dora the Explorer drives preschoolers ...
... ... all the treatments you might hope to want or need for the sunny weather to come! ... London, UK (PRWEB) June 19, 2010 -- The summer ... start looking your best. Fear not, for anyone stuck in London without so much as a grain ...
... ... Services, Inc. to Put Evidence-Based Medicine into Practice with Via Oncology Pathways ... Pittsburgh (PRWEB) June ... to improve as a result of wider application of Via Oncology™ Pathways, evidenced-based clinical ...
Cached Medicine News:Health News:Can multiple sclerosis attacks be minimized in a war zone? 2Health News:Young children are skilled negotiators 2Health News:Flame Retardant May Up Risk of Thyroid Problems in Pregnancy 2Health News:Cartoon Characters Sell Kids on Unhealthy Foods 2Health News:Cartoon Characters Sell Kids on Unhealthy Foods 3Health News:Summer is Here - The Best Value Luxury Manicures, Spa Packages and Spa Waxing from Kuno Tierra, Mayfair Spa 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 3
Acuvue 2 Colours features a special color-enhancing layer. So you get truly vivid, yet natural color....
... The Vasculight VS system improves the appearance ... freckles), most benign brown pigments, telangiectasias, and ... Intense Pulsed Light (IPLTM) treats pigmentary sun ... unique, combined approach of IPL and the ...
... in an upgradeable skin treatment system. ... of photo-aged skin, removes age spots ... and broken capillaries through a process ... Intense,Pulsed Light (IPLTM) treat facial vascular ...
With a large white surface and a black X in the center, knockout really makes you look the heavyweight....
Medicine Products: